Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28236559 | 0.89 | — | — | |
| SCHEMBL27669078 | 0.89 | — | — | |
| SCHEMBL3263374 | 0.88 | CA2 (0.31) | CA2CA9 | |
| SCHEMBL10614132 | 0.84 | — | — | |
| SCHEMBL3167586 | 0.84 | CA2 (0.30) | CA2 | |
| SCHEMBL253069 | 0.81 | CA2 (0.33) | CA2CA9 | |
| SCHEMBL10843647 | 0.79 | — | — | |
| SCHEMBL8079764 | 0.78 | — | — | |
| SCHEMBL1194013 | 0.77 | — | — | |
| SCHEMBL709424 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 407 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016022113-A1 | DIVERTER COMPOSITION INCLUDING RHEOLOGICALLY-MODIFIED INVERT EMULSION | HALLIBURTON ENERGY SERVICES, INC. (US) | 2016-02-11 | — | — | WO | claimed |
| WO-2015061342-A1 | METHODS FOR TREATMENT OF A SUBTERRANEAN FORMATION | HALLIBURTON ENERGY SERVICES, INC. (US) | 2015-04-30 | — | — | WO | claimed |
| WO-2015041679-A1 | DRILLING FLUID COMPOSITION INCLUDING VISCOSIFIER AND METHOD OF USING THE SAME | HALLIBURTON ENERGY SERVICES, INC. (US) | 2015-03-26 | — | — | WO | claimed |
| WO-2015034488-A1 | HYDROLYZABLE COMPOUNDS FOR TREATMENT OF A SUBTERRANEAN FORMATION AND METHODS OF USING THE SAME | HALLIBURTON ENERGY SERVICES, INC. (US) | 2015-03-12 | — | — | WO | claimed |
| EP-2076132-B1 | P-TOLUENE SULFONIC ACID SALT OF 5-AMINO-3-(2'-O-ACETYL-3'-DEOXY-BETA -D-RIBOFURANOSYL)-3H-THIAZOLE [4, 5-D]PYRIMIDINE-2-ONE AND METHODS FOR PREPARATION | ANADYS PHARMACEUTICALS INC (US) | 2012-07-11 | — | — | EP | claimed |
| US-8193342-B2 | Method for preparing furanose compounds | ANADYS PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | claimed |
| US-20110172447-A1 | METHOD FOR PREPARING FURANOSE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | claimed |
| CN-100569746-C | Arylbis (perfluoroalkylsulfonyl) methane and metal salts thereof, and process for producing the same | JAPAN SCIENCE & TECH AGENCY (JP) | 2009-12-16 | — | — | CN | claimed |
| US-20090197826-A1 | P-Toluene Sulfonic Acid Salt of 5-Amino-3-(2'-O-Acetyl-3'-Deoxy-Beta-D-Ribofuranosyl)-3H-Thiazole[4,5-d]pyrimidine-2-one and Methods for Preparation | ANADYS PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | US | claimed |
| EP-2076132-A1 | P-TOLUENE SULFONIC ACID SALT OF 5-AMINO-3-(2'-O-ACETYL-3'-DEOXY-BETA -D-RIBOFURANOSYL)-3H-THIAZOLE [4, 5-D]PYRIMIDINE-2-ONE AND METHODS FOR PREPARATION | Anadys Pharmaceuticals, Inc. (US) | 2009-07-08 | — | — | EP | claimed |
| WO-2000069875-A9 | C-2 MODIFIED ERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2002-02-21 | — | — | WO | claimed |
| WO-2000069875-A1 | C-2 MODIFIED ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 2000-11-23 | — | — | WO | claimed |
| EP-0935601-A2 | ARYLAMINO FUSED PYRIDINES AND PYRIMIDINES | Du Pont Pharmaceuticals Company (US) | 1999-08-18 | — | — | EP | claimed |
| EP-0922050-A1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1999-06-16 | — | — | EP | claimed |
| US-5750510-A | ANTIBIOTICS | ABBOTT LABORATORIES (US) | 1998-05-12 | — | — | US | claimed |
| WO-1997042205-A1 | 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 1997-11-13 | — | — | WO | claimed |
| WO-1997035539-A2 | ARYLAMINO FUSED PYRIDINES AND PYRIMIDINES | DU PONT PHARMACEUTICALS COMPANY (US) | 1997-10-02 | — | — | WO | claimed |
| CN-1041583-A | MUSCARMIC RECEPTOR ANTAGONISTS | PFIZER (US) | 1990-04-25 | — | — | CN | claimed |
| CN-1038451-A | Antiarrhythmics | PFIZER LTD (GB) | 1990-01-03 | — | — | CN | claimed |
| EP-0232954-A2 | Heterocyclic sulphonamides | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-08-19 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197826-A1 | P-Toluene Sulfonic Acid Salt of 5-Amino-3-(2'-O-Acetyl-3'-Deoxy-Beta-D-Ribofuranosyl)-3H-Thiazole[4,5-d]pyrimidine-2-one and Methods for Preparation | DPYD, APRT, TYMS | CA2 1924/4885CA9 1880/4885 |
| US-20110172447-A1 | METHOD FOR PREPARING FURANOSE COMPOUNDS | DPYD, TYMS, TST | CA2 2156/4885CA9 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.